Results 61 to 70 of about 37,814 (299)

Intravitreal ranibizumab, with or without filter? [PDF]

Acta Ophthalmologica, 2011
of 30 and 50 years (Yannuzzi 1986; Wang et al. 2008). Rarely, the presentation of exudative retinal detachments has been reported in younger patients in association with leukaemia (Stewart et al. 1989). These three young patients had all of the typical clinical characteristics of CSC, and to our knowledge, there is no previous report of CSC in patients
Eugenia Sanchis-Merino, José M. Ruiz-Moreno, Javier A. Montero   +2 more
openaire   +3 more sources

Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol. [PDF]

, 2020
AimTo show the characteristics and outcomes of patients with neovascular age-related macular degeneration (nAMD) who had extended remission (ER) while on a pro re nata (PRN) treatment protocol.MethodsThis was a retrospective case-control study of a ...
Amador-Patarroyo, Manuel J, Cheng, Lingyun, Dans, Kunny C, Freeman, William R, Lin, Tiezhu, Meshi, Amit, Muftuoglu, Ilkay Kilic   +6 more
core  

Integrated results from the COPERNICUS and GALILEO studies. [PDF]

, 2017
OBJECTIVES: To report on the efficacy and safety of intravitreal aflibercept in patients with macular edema secondary to central retinal vein occlusion (CRVO) in an integrated analysis of COPERNICUS and GALILEO.
Ahlers, Christiane, Asmus, Friedrich, Boyer, David S., Clark, W. Lloyd, Haller, Julia A., Holz, Frank G., Korobelnik, Jean-Francois, Ogura, Yuichiro, Pielen, Amelie, Rittenhouse, Kay D., Saroj, Namrata, Stemper, Brigitte, Vitti, Robert, Zeitz, Oliver   +13 more
core   +3 more sources

Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial [PDF]

, 2015
Purpose: To evaluate the efficacy and safety of dexamethasone intravitreal implant 0.7 mg (DEX) as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration (nvAMD). Procedures: This was a 6-month, single-masked, multicenter study.
Adnan Tufail, Ayala Pollack, Baruch D. Kuppermann, Ching-Chi Liu, Dov Weinberger, Jean Lou, Michael Singer, Michaella Goldstein, null null, Raj K. Maturi, Scott M. Whitcup, Xiao-Yan Li   +11 more
core   +1 more source

Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease

JAMA ophthalmology, 2020
Key Points Question Does a treat-and-extend approach with potentially less frequent anti-vascular endothelial growth factor injections and visits provide visual outcomes not worse than monthly ranibizumab injections in patients with neovascular acute ...
P. Kertes, I. Galić, M. Greve, Geoff Williams, Jason Baker, M. Lahaie, T. Sheidow   +6 more
semanticscholar   +1 more source

Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme [PDF]

, 2014
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.Peer reviewedPublisher ...
A D Morris, Cheng, D T Cromie, D W M Pearson, Elman, G P Leese, Ghafour, H C Looker, H M Colhoun, Hammes, J A McKnight, J A Olson, J Doig, Klein, Klein, Klein, Kohner, LeCaire, Leese, Leese, Looker, Looker, M W Black, Misra, Murgatroyd, N Lee, Olson, Pandit, Philip, R S Lindsay, Roy, S H Wild, S O Nyangoma, S Philip, Stratton, van Leiden, Zhang   +36 more
core   +6 more sources

Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model

International Journal of Ophthalmology, 2013
AIM:To compare the efficacies of subconjunctival bevacizumab, ranibizumab, and pegaptanib sodium injections for the inhibition of corneal neovascularization in an experimental rat model.METHODS:Sixteen corneas of 16 rats were chemically cauterized and ...
Cem Küçükerdönmez, Veysi Öner, Ebru Eren Akar, Yonca Aydın Akova   +3 more
doaj   +1 more source

Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema. [PDF]

PLoS ONE, 2014
OBJECTIVE: To evaluate if a standardized combination therapy regimen, utilizing 3 monthly ranibizumab injections followed by navigated laser photocoagulation, reduces the number of total ranibizumab injections required for treatment of diabetic macular ...
Raffael Liegl, Julian Langer, Florian Seidensticker, Lukas Reznicek, Christos Haritoglou, Michael W Ulbig, Aljoscha S Neubauer, Anselm Kampik, Marcus Kernt   +8 more
doaj   +1 more source

Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

International Journal of Retina and Vitreous, 2021
Background Razumab™ (world’s first biosimilar ranibizumab) is approved for several macular disorders including wet age-related macular degeneration (AMD). We evaluated the safety and efficacy of biosimilar ranibizumab in wet AMD. Methods This prospective,
Shashikant Sharma, Vishali Gupta, A. Maiti, S. Natesh, S. Saxena, V. Dave, Vimal P. Parmar, Raju Sampangi, H. Murthy, Sandhya Dharwadkar, N. Yadav, S. Joshi, Rahul Mayor, D. Ratra, S. Basu, N. Goel, A. Chaturvedi, Ronak Patel, V. Jose   +18 more
semanticscholar   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

BMEMat, EarlyView.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen, Ying Yao, Yan Zhang, Xinyu Shi, Ling Bai, Yang Zhong, Yan Zhang, Kun Zhang   +7 more
wiley   +1 more source